Skip to main content
Journal cover image

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

Publication ,  Journal Article
Morse, MA; Bradley, DA; Keler, T; Laliberte, RJ; Green, JA; Davis, TA; Inman, BA
Published in: Expert Rev Vaccines
June 2011

Cancer vaccines have demonstrated clinical benefit, however greater efficacy could be achieved by enhancing their immunogenicity. Owing to cancer vaccines depending on uptake and cross-presentation of tumor antigens by antigen-presenting cells (APCs), we hypothesized that greater immunogenicity would accompany strategies that direct antigen to APC-expressed mannose receptors, initiating a pathway increasing class I and II presentation to T cells. CDX-1307 consists of a human monoclonal antibody targeting the mannose receptor, fused to the human chorionic gonadotropin-β chain (hCG-β), a tumor antigen frequently expressed by epithelial cancers including bladder cancer. In Phase I studies of cancer patients, CDX-1307 was well tolerated and induced significant hCG-β-specific cellular and humoral immune responses when co-administered with GM-CSF and the Toll-like receptor agonists resiquimod and poly-ICLC. An ongoing Phase II trial evaluates CDX-1307 in patients with newly diagnosed, resectable, hCG-β-expressing bladder cancer, where low tumor burden and early intervention may provide greater potential for benefit.

Duke Scholars

Published In

Expert Rev Vaccines

DOI

EISSN

1744-8395

Publication Date

June 2011

Volume

10

Issue

6

Start / End Page

733 / 742

Location

England

Related Subject Headings

  • Virology
  • Urinary Bladder Neoplasms
  • Urinary Bladder
  • Treatment Outcome
  • T-Lymphocytes
  • Recombinant Fusion Proteins
  • Receptors, Cell Surface
  • Muscles
  • Mannose-Binding Lectins
  • Mannose Receptor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morse, M. A., Bradley, D. A., Keler, T., Laliberte, R. J., Green, J. A., Davis, T. A., & Inman, B. A. (2011). CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines, 10(6), 733–742. https://doi.org/10.1586/erv.11.20
Morse, Michael A., Deborah A. Bradley, Tibor Keler, Robert J. Laliberte, Jennifer A. Green, Thomas A. Davis, and Brant A. Inman. “CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.Expert Rev Vaccines 10, no. 6 (June 2011): 733–42. https://doi.org/10.1586/erv.11.20.
Morse MA, Bradley DA, Keler T, Laliberte RJ, Green JA, Davis TA, et al. CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines. 2011 Jun;10(6):733–42.
Morse, Michael A., et al. “CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.Expert Rev Vaccines, vol. 10, no. 6, June 2011, pp. 733–42. Pubmed, doi:10.1586/erv.11.20.
Morse MA, Bradley DA, Keler T, Laliberte RJ, Green JA, Davis TA, Inman BA. CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines. 2011 Jun;10(6):733–742.
Journal cover image

Published In

Expert Rev Vaccines

DOI

EISSN

1744-8395

Publication Date

June 2011

Volume

10

Issue

6

Start / End Page

733 / 742

Location

England

Related Subject Headings

  • Virology
  • Urinary Bladder Neoplasms
  • Urinary Bladder
  • Treatment Outcome
  • T-Lymphocytes
  • Recombinant Fusion Proteins
  • Receptors, Cell Surface
  • Muscles
  • Mannose-Binding Lectins
  • Mannose Receptor